^
Association details:
| Biomarker: | EGFR exon 19 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.
Published date:
12/10/2021
Excerpt:
...complex mutations in 24% of the patients with NSCLC who were evaluated for the study....Exon 19 or exon 21 mutations were present in 22 patients in the complex mutation group, and PFS time of these patients was 17.4 months (95% CI 6.6-28.2) and OS was 24.3 months (95% CI 0.0-89.4)….Overall response rate of the patients was similar in the erlotinib and afatinib arms (53.3% vs 52%, p= 0.218) (Table 3).
DOI:
10.21203/rs.3.rs-1125056/v1
